Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2012

01.06.2012 | Research Article

Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria

verfasst von: Elisabete Pinto Borges, Manuel Morgado, Ana Filipa Macedo

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background Underuse of medication considered beneficial is particularly common in elderly patients. A new Screening Tool to Alert Doctors to the Right Treatment (START) has been published to identify potential prescribing omissions. Objective To quantify and characterize potential prescribing omissions of cardiovascular risk management therapy using START criteria. Setting This study was conducted in the Stroke Unit of the university teaching hospital of Cova da Beira Hospital Centre, Covilhã, located in the Eastern Central Region of Portugal. Method During 6 months, the medical files of all elderly patients (age ≥ 65 years) admitted with acute cardiovascular disease were reviewed and the START criteria applied to the information of medication, at admission and at the time of discharge from the hospital Stroke Unit. Main outcome measure Potential prescribing omissions of cardiovascular and endocrine pharmacological therapy were identified and the difference in the potential prescribing omissions between admission and discharge from hospital Stroke Unit was also evaluated. Results At the time of admission to the Stroke Unit, 101 potential prescribing omissions were found in 68.1 % (n = 91) of elderly (average 1.11 omissions per patient), of which 84.2 % (n = 85) were corrected at the time of discharge. In 14 patients, 16 omissions found at admission were not corrected during hospitalization, and in 5 patients 5 new omissions were detected. Conclusion Prescribing omissions of beneficial drugs are highly prevalent in acutely ill admitted to a Stroke Unit. START criteria represent a simple, evidence-based and easy-to-use tool to screen underuse of cardiovascular risk management therapy in elderly patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hashimoto K, Tabata K. Population aging, health care and growth. J Popul Econ. 2010;23:571–93.CrossRef Hashimoto K, Tabata K. Population aging, health care and growth. J Popul Econ. 2010;23:571–93.CrossRef
2.
Zurück zum Zitat Preventing Chronic Diseases. A Vital Investment: WHO Global Report. Geneva: World Health Organization, 2005. pp 200. CHF 30.00. ISBN 92 4 1563001. Int J Epidemiol. 2006; 35(4):1107. Preventing Chronic Diseases. A Vital Investment: WHO Global Report. Geneva: World Health Organization, 2005. pp 200. CHF 30.00. ISBN 92 4 1563001. Int J Epidemiol. 2006; 35(4):1107.
4.
Zurück zum Zitat Hajjar ER, Cafiero AC, Halon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–55.PubMedCrossRef Hajjar ER, Cafiero AC, Halon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–55.PubMedCrossRef
5.
Zurück zum Zitat Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21(12):793–811.PubMedCrossRef Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21(12):793–811.PubMedCrossRef
6.
Zurück zum Zitat Halon JT, Lindblad CI, Hajjar ER, McCarthy TC. Update on drug-related problems in the elderly. Am J Geriatr Pharmacother. 2003;1:38–43.CrossRef Halon JT, Lindblad CI, Hajjar ER, McCarthy TC. Update on drug-related problems in the elderly. Am J Geriatr Pharmacother. 2003;1:38–43.CrossRef
7.
Zurück zum Zitat Wright RM, Sloane R, Pieper CF, Ruby-Scelsi C, Twersky J, Schmader KE, Hanlon JT. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271–80.PubMedCrossRef Wright RM, Sloane R, Pieper CF, Ruby-Scelsi C, Twersky J, Schmader KE, Hanlon JT. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271–80.PubMedCrossRef
8.
Zurück zum Zitat Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in the elderly patients. Age Ageing. 1992;21(4):294–300.PubMedCrossRef Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in the elderly patients. Age Ageing. 1992;21(4):294–300.PubMedCrossRef
9.
Zurück zum Zitat Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention, ADE Prevention Study Group. JAMA. 1995;274(1):29–34.PubMedCrossRef Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention, ADE Prevention Study Group. JAMA. 1995;274(1):29–34.PubMedCrossRef
10.
Zurück zum Zitat Barry PJ, Gallagher P, Ryan C. Inappropriate prescribing in geriatric patients. Curr Psychiatry Rep. 2008;10:37–43.PubMedCrossRef Barry PJ, Gallagher P, Ryan C. Inappropriate prescribing in geriatric patients. Curr Psychiatry Rep. 2008;10:37–43.PubMedCrossRef
11.
Zurück zum Zitat Spinewine A, Schamader KE, Barbr N, Hughes C, Lapane KL, Swine C, Halon JT. Prescribing in elderly people 1 Appropriate prescribing in elderly people: how well can it be measured and optimized? Lancet. 2007;370(9582):173–84.PubMedCrossRef Spinewine A, Schamader KE, Barbr N, Hughes C, Lapane KL, Swine C, Halon JT. Prescribing in elderly people 1 Appropriate prescribing in elderly people: how well can it be measured and optimized? Lancet. 2007;370(9582):173–84.PubMedCrossRef
12.
Zurück zum Zitat Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing homes. Arch Intern Med. 1991;151(9):1825–32.PubMedCrossRef Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing homes. Arch Intern Med. 1991;151(9):1825–32.PubMedCrossRef
13.
Zurück zum Zitat Beers MH. Explicit criteria for determining potentially inappropriate medication use in elderly: an update. Arch Intern Med. 1997;157(14):1531–6.PubMedCrossRef Beers MH. Explicit criteria for determining potentially inappropriate medication use in elderly: an update. Arch Intern Med. 1997;157(14):1531–6.PubMedCrossRef
14.
Zurück zum Zitat Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103–7.PubMed Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103–7.PubMed
15.
Zurück zum Zitat Halon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR. A method assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.CrossRef Halon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR. A method assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.CrossRef
16.
Zurück zum Zitat Wenger NS, Shekelle PG. ACOVE investigators, assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(8):642–6.PubMed Wenger NS, Shekelle PG. ACOVE investigators, assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(8):642–6.PubMed
17.
Zurück zum Zitat Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening tool of older person’s prescriptions) and START (Screening tool to alert doctors to the right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.PubMed Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening tool of older person’s prescriptions) and START (Screening tool to alert doctors to the right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.PubMed
18.
Zurück zum Zitat Barry PJ, Gallagher P, Ryan C, O’Mahony D. START (screening tool to alert doctors to the right treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632–8.PubMedCrossRef Barry PJ, Gallagher P, Ryan C, O’Mahony D. START (screening tool to alert doctors to the right treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632–8.PubMedCrossRef
19.
Zurück zum Zitat Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28(19):2375–2414. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28(19):2375–2414.
20.
Zurück zum Zitat Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A, Banach M. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50:114–8.PubMedCrossRef Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A, Banach M. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50:114–8.PubMedCrossRef
21.
Zurück zum Zitat Guerra LC, Moreno MCF, Suero JA. Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. Eur J Intern Med. 2009;20:586–90.CrossRef Guerra LC, Moreno MCF, Suero JA. Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. Eur J Intern Med. 2009;20:586–90.CrossRef
22.
Zurück zum Zitat Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700–7.PubMedCrossRef Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700–7.PubMedCrossRef
23.
Zurück zum Zitat Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol. 2008;51:46–8.PubMedCrossRef Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol. 2008;51:46–8.PubMedCrossRef
24.
Zurück zum Zitat Ryan C, O’Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936–47. Ryan C, O’Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936–47.
25.
Zurück zum Zitat Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF, The OLDY (OLd people Drugs & dYsregulations) study group. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2007;65(1):130–3.PubMedCrossRef Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF, The OLDY (OLd people Drugs & dYsregulations) study group. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2007;65(1):130–3.PubMedCrossRef
26.
Zurück zum Zitat Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.PubMedCrossRef Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.PubMedCrossRef
27.
Zurück zum Zitat Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;6:845–54.CrossRef Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;6:845–54.CrossRef
28.
Zurück zum Zitat Broeiro P, Maio I, Ramos V. Polifarmacoterapia Estratégias de Racionalização, Dossier: prescrição em medicina geral e familiar. Rev Port Clin Geral. 2008;24:625–31. Broeiro P, Maio I, Ramos V. Polifarmacoterapia Estratégias de Racionalização, Dossier: prescrição em medicina geral e familiar. Rev Port Clin Geral. 2008;24:625–31.
29.
Zurück zum Zitat Pyszka LL, Seys Ranola TM, Milhans SM. Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools. Consult Pharm. 2010;25(6):365–73.PubMedCrossRef Pyszka LL, Seys Ranola TM, Milhans SM. Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools. Consult Pharm. 2010;25(6):365–73.PubMedCrossRef
30.
Zurück zum Zitat Amarenco P, Labreuche J, Lavalle P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–9.PubMedCrossRef Amarenco P, Labreuche J, Lavalle P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–9.PubMedCrossRef
31.
Zurück zum Zitat European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guideline for management of ischaemic stroke and transient ischaemic attack. 2008. Cerebrovasc Dis. 2008;25(5):457–507.CrossRef European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guideline for management of ischaemic stroke and transient ischaemic attack. 2008. Cerebrovasc Dis. 2008;25(5):457–507.CrossRef
32.
Zurück zum Zitat Smith SC, Allen J, Blair SN, Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease, 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–72.PubMedCrossRef Smith SC, Allen J, Blair SN, Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease, 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–72.PubMedCrossRef
33.
Zurück zum Zitat Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation and Prevention. Circulation. 2002;105(14):1735–43.PubMedCrossRef Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation and Prevention. Circulation. 2002;105(14):1735–43.PubMedCrossRef
34.
Zurück zum Zitat Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl. 2009; 11(Suppl A):A21–A25. Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl. 2009; 11(Suppl A):A21–A25.
35.
Zurück zum Zitat Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107(1):149–58.PubMedCrossRef Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107(1):149–58.PubMedCrossRef
36.
Zurück zum Zitat Fox K, Garcia MA, Ardissino D, Buzzman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341–81.PubMedCrossRef Fox K, Garcia MA, Ardissino D, Buzzman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341–81.PubMedCrossRef
37.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef
38.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial Hypertension. Eur Heart J. 2007;28(12):1462–536.PubMed Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial Hypertension. Eur Heart J. 2007;28(12):1462–536.PubMed
39.
Zurück zum Zitat Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822–7.PubMedCrossRef Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822–7.PubMedCrossRef
40.
Zurück zum Zitat Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651–745.PubMedCrossRef Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651–745.PubMedCrossRef
41.
Zurück zum Zitat Sirois C, Moisan J, Poirier P, Grégoire J-P. Underuse of cardioprotective treatment by the elderly with type 2 diabetes. Diabetes Metab. 2008;34(2):169–76.PubMedCrossRef Sirois C, Moisan J, Poirier P, Grégoire J-P. Underuse of cardioprotective treatment by the elderly with type 2 diabetes. Diabetes Metab. 2008;34(2):169–76.PubMedCrossRef
42.
Zurück zum Zitat Sigal R, Malcolm J, Meggison H. Prevention of cardiovascular events in diabetes. Clin Evid. 2005;14:501–21. Sigal R, Malcolm J, Meggison H. Prevention of cardiovascular events in diabetes. Clin Evid. 2005;14:501–21.
43.
Zurück zum Zitat Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.PubMedCrossRef Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.PubMedCrossRef
44.
Zurück zum Zitat Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.PubMedCrossRef Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.PubMedCrossRef
46.
Zurück zum Zitat Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009;59(558):43–8.PubMedCrossRef Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009;59(558):43–8.PubMedCrossRef
Metadaten
Titel
Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria
verfasst von
Elisabete Pinto Borges
Manuel Morgado
Ana Filipa Macedo
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2012
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9635-1

Weitere Artikel der Ausgabe 3/2012

International Journal of Clinical Pharmacy 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.